PGEN Positive Sentiment
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Monday, August 25, 2025 BiopharmaWatch Research 1 min read Key Takeaway: Precigen, Inc. announced its participation in two virtual fireside chats hosted by Cantor and H.C. Wainwright. The discussions will focus on the recent FDA approval of a therapy for recurrent respiratory papillomatosis. Key executives from Precigen will represent the company during these events, which are accessible via their website.
Full Press Release Details
GERMANTOWN, Md.,Aug. 25, 2025/PRNewswire/ --Precigen, Inc.(Nasdaq:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted byJennifer Kimof Cantor, and Swayampakula Ramakanth, PhD, of H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis.
Cantor Virtual Fireside ChatAugust 27, 2025,11 AM–12 PM ETHost:Jennifer Kim, Biotech Analyst, CantorParticipants:Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen
H.C. Wainwright Virtual Fireside ChatSeptember 2, 2025,11 AM–12 PM ETModerator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research,H.C. WainwrightParticipants:Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen
Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section atinvestors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®Precigen (Nasdaq:PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visitwww.precigen.comor follow us onLinkedInorYouTube.
Investor Contact:Steven M. HarasymTel: +1 (202) 365-2563[email protected]
Media Contact:Donelle M. Gregory[email protected]